Novel agent for treatment of Parkinson s disease in clinical development

Lundbeck has initiated phase I clinical trials with the
pharmaceutical candidate Lu AA47070 to investigate safety,
tolerability and the pharmacokinetic profile of the compound in
humans.

Lu AA47070 is a novel adenosine receptor antagonist that has been
shown to be efficacious in a number of animal models for neurological
diseases including models of Parkinson's disease. It is therefore
expected that Lu AA47070 may have a potential in certain neurological
indications and could be an alternative to e.g. dopamine agonists in
the treatment of Parkinson's disease."Lu AA47070 is a very promising compound with a unique profile and
has the potential to make a significant difference to for instance
patients suffering from Parkinson's disease," says Peter Høngaard
Andersen, Head of Research at Lundbeck. He continues: "Lu AA47070 is
discovered at Lundbeck and is our first compound within the neurology
area from our internal research."

About Parkinsons Disease
Parkinson's disease is a chronic, progressive neurodegenerative
condition. The exact cause of Parkinson's disease is not known and is
believed to be multifactorial involving genes, environmental factors
and aging.

Symptoms include tremor, slowness of movement, stiffness, gait and
posture problems. As the disease progresses, symptoms worsen, the
patient is likely to experience motor complications. Eventually, the
disease impairs the patient's ability to function.

Parkinson's disease affects men and women equally, and an estimated
four million people worldwide suffer from the disease. The disease
typically occurs at a late age, affecting approx. 1% of the
population over the age of 65. In 2006, the worldwide sales for drugs
to treat Parkinson's disease reached USD 3.1 billion.

The content of this release will have no influence on the Lundbeck
Group's financial result for 2007.

Lundbeck contacts


Investors:                    Media:

Jacob Tolstrup                Anders Schroll
Director, Corporate Reporting Head of Communication
+45 36 43 30 79               +45 36 43 20 81



                      ________________________

Stock Exchange Release No 302 - 13 November 2007

About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of drugs
for the treatment of psychiatric and neurological disorders. In 2006,
the company's revenue was DKK 9.2 billion (approximately EUR 1.2
billion or USD 1.6 billion). The number of employees is approximately
5,300 globally. For further information, please visit
www.lundbeck.com